bluuebunny/crossref_metadata_2025_split huggingface dataset:
Safety assessment of agricultural products and the pesticide regulation trend in China
Authors: Shao Yitian , Ni Jianwei , Zhou Shengjia , Wang Yiping , Jin Xuanxuan 
Published: August 2024

AbstractThe sustainable development of Chinese agriculture needs to coordinate the quality and quantity of agricultural products. To verify whether government regulation can promote agricultural development by controlling pesticides, the indices of government regulation, quantity and quality of agricultural products, and pesticide use per area of cropland were calculated, and a comprehensive evaluation index and the coupling degree and coordination degree of agricultural products were analyzed by coupling function. The results showed that the coupling and coordination degree of the quality and quantity of agricultural products and the comprehensive index are improving. The regulation of pesticide use per area of cropland is a key mechanism in promoting the coordinated development of agricultural product safety. The regulation trend of agricultural development in China is to reduce pesticide usage appropriately and expand the production-possibility frontier of agricultural products.
Graphical abstract
CAMKK2-AMPK axis endows dietary calcium and phosphorus levels with regulatory effects on lipid metabolism in weaned piglets
Authors: Miao Zhenyan , Sun Yanjie , Feng Zhangjian , Wu Qiwen , Yang Xuefen , Wang Li , Jiang Zongyong , Li Ying , Yi Hongbo 
Published: August 2024

Abstract
Background
In the realm of swine production, optimizing body composition and reducing excessive fat accumulation is critical for enhancing both economic efficiency and meat quality. Despite the acknowledged impact of dietary calcium (Ca) and phosphorus (P) on lipid metabolism, the precise mechanisms behind their synergistic effects on fat metabolism remain elusive.

Results
Research observations have shown a decreasing trend in the percentage of crude fat in carcasses with increased calcium and phosphorus content in feed. Concurrently, serum glucose concentrations significantly decreased, though differences in other lipid metabolism-related indicators were not significant across groups. Under conditions of low calcium and phosphorus, there is a significant suppression in the expression of FABPs, CD36 and PPARγ in the jejunum and ileum, leading to inhibited intestinal lipid absorption. Concurrently, this results in a marked increase in lipid accumulation in the liver. Conversely, higher levels of dietary calcium and phosphorus promoted intestinal lipid absorption and reduced liver lipid accumulation, with these changes being facilitated through the activation of the CAMKK2/AMPK signaling pathway by high-calcium-phosphorus diets. Additionally, the levels of calcium and phosphorus in the diet significantly altered the composition of liver lipids and the gut microbiota, increasing α-diversity and affecting the abundance of specific bacterial families related to lipid metabolism.

Conclusion
The evidence we provide indicates that the levels of calcium and phosphorus in the diet alter body fat content and lipid metabolism by modulating the response of the gut-liver axis to lipids. These effects are closely associated with the activation of the CAMKK2/AMPK signaling pathway.
CD105+CAF-derived exosomes CircAMPK1 promotes pancreatic cancer progression by activating autophagy
Authors: He Zhiwei , Li Xiushen , Chen Shiyu , Cai Kun , Li Xiaowu , Liu Hui 
Published: August 2024

AbstractPrevious studies have shown that the heterogeneity of tumor-associated fibroblasts (CAFs) in the tumor microenvironment may play a critical role in tumorigenesis; however, the biological function of CAFs in pancreatic cancer is still controversial. In this study, we found that CD105-positive (CD105+) CAF-derived exosomes significantly promoted the proliferative and invasive metastatic abilities of pancreatic cancer cells. Furthermore, RNA-seq and qRT‒PCR experiments revealed circAMPK1 as a key molecule in exosomes from CD105+ CAFs that mediates the malignant progression of pancreatic cancer. Furthermore, we demonstrated that circAMPK1 encodes a novel protein (AMPK1-360aa) in pancreatic cancer cells. This protein competes with AMPK1 to bind to the ubiquitination ligase NEDD4, which inhibits AMPK1 protein degradation and ubiquitination and thereby increases AMPK1 levels. Finally, we demonstrated that AMPK1-360aa induces cellular autophagy via NEDD4/AMPK1 to promote the proliferation and invasion of pancreatic cancer cells. In summary, circAMPK1 in CD105+ CAF-derived exosomes may mediate pancreatic cancer cell proliferation and invasive metastasis by inducing autophagy in target cells. Moreover, circAMPK1 may competitively bind to ubiquitinating enzymes through the encoded protein AMPK1-360aa, which in turn inhibits the ubiquitination-mediated degradation of AMPK1 and contributes to the upregulation of AMPK1 expression, thus inducing cellular autophagy to mediate the malignant progression of pancreatic cancer.
Cell membrane patches transfer CAR molecules from a cellular depot to conventional T cells for constructing innovative fused-CAR-T cells without necessitating genetic modification
Authors: Hu Jing , Zhong Luyi , Wang Yiqiu , Hu Shiyi , Zhang Lijiaqi , Tian Qingchang 
Published: August 2024

AbstractChimeric antigen receptor (CAR) serves as the foundational element of CAR-T cells. Exogenous CAR molecules can exert functional effects on allogeneic T cells, leading to their activation and subsequent functional alterations. Here we show a new method based on this biological principle: the transfer of CAR molecules from exogenous cells to the membrane of receptor T cells. This process facilitates receptor T cell to recognize target antigens and induces their activation. These patches imbued normal T cells with enhanced tumor targeting capabilities and activated their inherent killing functions. This method’s efficacy introduces an approach for constructing non-genetically manipulated CAR-T cells and holds potential for application to other immune cells.
Graphical Abstract
Modulatory effects of selenium nanoparticles against drought stress in some grapevine rootstock/scion combinations
Authors: Daler Selda , Korkmaz Nesrin , Kılıç Tuğba , Hatterman-Valenti Harlene , Karadağ Ahmet , Kaya Ozkan 
Published: August 2024

Abstract
Background
Drought is a significant abiotic stress that adversely affects plant growth, development, and metabolic processes, thereby reducing plant yield, quality, and production, and threatening global food security. In recent years, nanotechnology has emerged as a promising strategy to overcome the existing environmental challenges and has been tested on some plant species. But it is still awaiting investigation for grapevines. The aim of this study was to investigate the potential of selenium nanoparticles (Se-NPs) to modulate some morphological, physiological, and biochemical parameters in grapevine saplings (5 BB/Crimson Seedless, 41 B/Crimson Seedless, and 1103 P/Crimson Seedless) under drought stress conditions.

Results
In the study, Se-NP solutions at different concentrations (0 (control), 1, 10, and 100 ppm) were applied by the spray method to wet the entire green surface of grapevine saplings grown under well-irrigated (90–100% field capacity) and drought stress (40–50% field capacity) conditions. Our results showed that 10 ppm Se-NP concentration had the most positive effect, 1 ppm concentration showed limited effects, and 100 ppm concentration led to toxic effects, especially when combined with drought conditions. Se-NP applications at 10 ppm concentration improved the growth parameters (leaf number, leaf area, root fresh and dry weight, shoot fresh and dry weight, etc.) and increased the SPAD index of grapevine saplings under both normal and drought conditions. Additionally, 10 ppm Se-NP applications improved the relative water content (RWC) and stomatal conductance values, proportional to the increases in protein content. On the other hand, under drought conditions, the drought index, leaf temperature, membrane damage index, hydrogen peroxide (H2O2) content, and malondialdehyde (MDA) levels significantly decreased as a result of 10 ppm Se-NP applications, showing an opposite trend. Furthermore, the levels of proline, total phenolics, and antioxidant enzymes (CAT, SOD, and APX) that rose significantly due to drought stress were reduced by 10 ppm Se-NP applications, which also helped to lessen the oxidative stress caused by the drought.

Conclusion
The study concluded that foliar application of Se-NPs at 10 ppm significantly enhances drought tolerance in grapevine saplings by improving antioxidant defense, proline and protein accumulation, and overall growth, while lower concentrations are less effective and higher concentrations can cause phytotoxicity. These findings indicate that Se-NPs applications may hold promise not only for grapevines but also for mitigating drought stress effects and improving productivity in other economically important fruit species, warranting further exploration across diverse crop systems.

Graphical Abstract
Left ventricular thrombus routine screening with contrast echocardiography in patients with anterior ST-elevation myocardial infarction: is it worth it?
Authors: Correia Joana Laranjeira , Ferreira Gonçalo R. M. , Fiuza João Gouveia , Almeida Mariana Duarte , Coelho Joana , Correia Emanuel , Correia José Miguel , Moreira Davide , Craveiro Nuno , Gonçalves Maria Luísa , Neto Vanda Devesa 
Published: August 2024

Abstract
Background
Left ventricular (LV) thrombus has a higher incidence among patients with anterior ST-elevation myocardial infarction (STEMI) when compared to other types of acute myocardial infarction and is associated with worse prognosis. The management of LV thrombus diagnosis remains challenging. Contrast echocardiography (transthoracic echocardiography, TTE) has shown potential in improving the accuracy for its diagnosis, thereby influencing treatment strategies concerning antithrombotic/anticoagulation therapy. The aim of this study was to assess the effectiveness of contrast TTE as a routine screening method for detecting LV thrombus in the acute phase of anterior STEMI.

Methods
A prospective, single center, randomized controlled trial was conducted among patients with anterior STEMI. The study group underwent contrast TTE, while the control group received a conventional approach. Demographical, clinical, and diagnostic data were collected. Thrombus detection rates were compared between groups.

Results
A total of 68 patients were included (32 in the study group and 36 in the control group). No substantial baseline differences were observed between groups. Thrombus detection rate was 25.0% in the study group and 13.9% in the control group, however these results did not reach statistical significance (P = 0.24). The prevalence of anterior/apical aneurysm was higher in the study group (46.9% vs. 22.2%, P = 0.03).

Conclusions
Conventional TTE may be adequate for diagnosing LV thrombus in the acute phase of anterior STEMI; however, further larger-scale and multicenter studies are necessary to obtain more robust and conclusive results. Ultrasound contrast may play a significant role in the detection of anterior/apical aneurysms, which are known risk factors for the subsequent development of thrombus.

Trial registration
NCT06480929 (ClinicalTrials.gov, Retrospectively registered).
Testamentary capacity
Authors: Burns Alistair , Series Hugh , Warner James , Bishop Andrew , McKean James 
Published: August 2024

SUMMARYTo make a valid will, a person should be able to understand the nature and consequences of doing so, the extent of their estate and the claims others may have on it. No disorder of mind should be present that would affect their testamentary decisions, and clinicians are therefore often asked to give an opinion on whether a person has testamentary capacity. This article discusses the legal issues involved, with reference to UK case law (in particular, the legal test of Banks v Goodfellow (1870)), and outlines the requirements of testamentary capacity assessment (including retrospective assessments), the clinician's responsibilities when requested by a solicitor to make an assessment of capacity (‘the golden rule’) and what they might expect if appearing in court to give expert witness regarding testamentary capacity. Fictitious case studies are presented illustrating certain points in testamentary capacity assessment.
Effect of nature on the mental health and well-being of children and adolescents: meta-review
Authors: Lomax Tessa , Butler Joseph , Cipriani Andrea , Singh Ilina 
Published: August 2024

BackgroundUrbanisation is taking place worldwide and rates of mental illness are rising. There has been increasing interest in ‘nature’ and how it may benefit mental health and well-being.AimsTo understand how the literature defines nature; what the characteristics of the nature intervention are; what mental health and well-being outcomes are being measured; and what the evidence shows, in regard to how nature affects the mental health and well-being of children and adolescents.MethodA meta-review was conducted, searching three databases for relevant primary and secondary studies, using key search terms including ‘nature’ and ‘mental health’ and ‘mental well-being’. Inclusion criteria included published English-language studies on the child and adolescent population. Authors identified the highest quality evidence from studies meeting the inclusion criteria. Data were extracted and analysed using descriptive content analysis.ResultsSixteen systematic reviews, two scoping reviews and five good quality cohort studies were included. ‘Nature’ was conceptualised along a continuum (the ‘nature research framework’) into three categories: a human-designed environment with natural elements; a human-designed natural environment; and a natural environment. The nature ‘intervention’ falls into three areas (the ‘nature intervention framework’): access, exposure and engagement with nature, with quantity and quality of nature relevant to all areas. Mental health and well-being outcomes fit along a continuum, with ‘disorder’ at one end and ‘well-being’ at the other. Nature appears to have a beneficial effect, but we cannot be certain of this.ConclusionsNature appears to have a beneficial effect on mental health and well-being of children and adolescents. Evidence is lacking on clinical populations, ethnically diverse populations and populations in low- and middle-income countries. Our results should be interpreted considering the limitations of the included studies and confidence in findings.
Pooled analysis by best confirmed response to trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+ metastatic breast cancer (mBC) from DESTINY-Breast-01, -02, and -03.
Authors: Saura Cristina , Cortés Javier , Modi Shanu , Kim Sung-Bae , Hamilton Erika P. , Hurvitz Sara A. , Krop Ian E. , Curigliano Giuseppe , Iwata Hiroji , Im Seock-Ah , Herbolsheimer Pia Maarit , Karnoub Maha , Gambhire Dhiraj , Egorov Anton , Andre Fabrice 
Published: August 2024

1023 Background: DESTINY-Breast (DB)-01, -02, and -03 evaluated T-DXd in pts with HER2+ mBC who received ≥1 prior line of therapy. These studies showed confirmed objective response rates by independent central review (ICR; blinded for DB-02 and -03) of 62%, 70%, and 79% and complete response (CR) rates of 7%, 14%, and 21%, respectively, with T-DXd. We report a pooled analysis according to pts’ best confirmed response in DB-01, -02, or -03. Methods: Endpoints included best confirmed response per (blinded) ICR ([B]ICR) based on RECIST v1.1, duration of response (DoR), progression-free survival (PFS) by (B)ICR, overall survival (OS), and safety. Results: The median (range) duration of T-DXd treatment for pts with a CR, partial response (PR), or stable disease (SD)/progressive disease (PD) was 27.4 (4.5-45.1) mo, 14.0 (2.1-39.3) mo, or 6.2 (0.7-40.1) mo, respectively. Of 834 evaluable pts assigned to T-DXd in DB-01, -02, or -03, 125 (15.0%) had a CR, 477 (57.2%) had a PR, and 232 (27.8%) had SD/PD. Pts with CR had a median of 2 prior regimens (range, 1-11) in the metastatic setting, whereas pts with PR or SD/PD had a median of 3 prior regimens. As shown in the Table, pts with CR had more favorable PFS and OS outcomes vs pts with PR or SD/PD. The proportion of pts with drug-related, serious treatment-emergent adverse events (TEAEs) was numerically lower in pts with CR (8.0%) than those with PR (12.4%) or SD/PD (15.5%). Pts with CR also had numerically lower rates of drug-related TEAEs associated with T-DXd discontinuation (14.4% vs 17.8% or 16.8%) and adjudicated drug-related interstitial lung disease (ILD)/pneumonitis (8.8% [0 fatal] vs 15.1% [2 fatal] or 11.6% [5 fatal]) and longer median time to first ILD onset (461 days vs 211 or 125 days) vs pts with PR or SD/PD. Conclusions: Pts treated with T-DXd benefited from durable responses resulting in prolonged PFS and OS, especially those with a CR. Despite longer treatment duration in responders, safety remained generally manageable and did not result in a higher percentage of pts with TEAEs over time. These results further support the use of T-DXd across broad pt groups with HER2+ mBC. Clinical trial information: NCT03248492 , NCT03523585 , NCT03529110 . [Table: see text]
Symptom management through electronic patient-reported outcome (ePRO)-based intervention in patients with breast cancer treated with abemaciclib: Primary results from the LIBRA study, a phase II randomized controlled trial.
Authors: Takano Toshimi , Hayashida Tetsu , Nagayama Aiko , Ozaki Yukinori , Takahashi Maiko , Seki Tomoko , Yokoe Takamichi , Aoyama Yosuke , Kizawa Rika , Nishimura Meiko , Hosonaga Mari , Hara Fumikata , Kobayashi Takayuki , Ueno Takayuki , Kitagawa Yuko 
Published: August 2024

11110 Background: We have developed a system using LINE, a widely-used social network service in Japan, for rapid collection of ePROs based on the PRO-CTCAE criteria. To evaluate the effectiveness of intervention through this system in reducing diarrhea frequency and enhancing quality of life (QOL) in patients treated with abemaciclib, we conducted a randomized controlled trial. Methods: Patients with hormone receptor-positive advanced breast cancer scheduled to begin abemaciclib treatment were randomized to the intervention and control arms with 1:1 ratio. The LINE-ePRO system was used to monitor symptoms daily in both arms. In the intervention arm, expert medical staffs contacted patients via phone when symptoms met certain criteria, whereas patients in the control arm received standard care. The primary endpoint was the increase in the number of defecations from baseline during 28 days. The secondary endpoints included the increase in the number of defecations from baseline during 56 days, other symptoms monitored via the LINE-ePRO system, QOL evaluated by EORTC QLQ C-30 and EQ-5D-5L, relative dose intensity (RDI), treatment interruption rate, progression-free survival (PFS), and overall survival (OS). This study (LIBRA, UMIN000045432) is funded by Eli Lilly. Results: Between Jan 2022 and Apr 2023, 60 women were enrolled and 58 (29 in each arm) were analyzed in this study. Median age was 57.5 years (range 43-80), 93% of patients were post-menopausal, 71% received abemaciclib as first-line treatment, and 74% were treated in combination with aromatase inhibitors. The increase in the number of defecations from baseline was significantly lower in the intervention arm compared to the control arm both during 28 days (0.64 vs. 1.21 per day, p=0.003) and during 56 days (0.55 vs. 1.18 per day, p=0.0004). No significant difference was observed in other symptoms between the arms. In the EORTC QLQ C-30 scales, global health status/QOL (mean score change from baseline to after one cycle of abemaciclib treatment: 0 vs. -13.5, p=0.038) and diarrhea (20.7 vs. 32.2, p=0.049) were better in the intervention arm. The treatment interruption and dose reduction rates were 41.4 and 31.0% in the intervention arm, and 31.0 and 27.6% in the control arm, respectively. The mean RDI of abemaciclib was numerically lower in the intervention arm (73.5% vs. 84.8%). Conclusions: This study is the first randomized trial to demonstrate that the intervention based on daily ePROs reduces the frequency of diarrhea in patients with advanced breast cancer treated with abemaciclib. Clinical trial information: UMIN000045432.
Durvalumab and tremelimumab versus doxorubicin in previously untreated patients with advanced or metastatic soft tissue sarcoma: Patient-reported outcomes (PROs) of the randomized phase II MEDISARC study (AIO-STS-0415).
Authors: Grünwald Viktor , Hermes Barbara , Tuchscherer Armin , Bauer Sebastian , Hamacher Rainer , Pink Daniel , Lindner Lars H , Gröschel Stefan , Reichardt Peter , Richter Stephan , Oing Christoph , Augustin Marinela , Crysandt Martina Margrit , Kortüm Martin , Kasper Bernd , Fischer Marc , Ivanyi Philipp 
Published: August 2024

11519 Background: The randomized phase II MEDISARC trial (NCT03317457) tested durvalumab (DUR) and tremelimumab (TRE) vs. doxorubicin (DOX) in soft tissue sarcoma (STS) patients in first-line therapy. The study showed no PFS benefit (HR 1.22; 95%CI 0,90-1.64; P = .4049), but a trend in prolonged OS (HR 0.73; 95%CI 0.54-0.99; P = .185) in favor of DUR-TRE (Grünwald et al. ESMO 2024: LBA90). The current analysis reports on patient reported outcomes (PROs) under treatment. Methods: We utilized EORTC QLQ-C30 printed questionnaires in randomized patients. PRO were assessed during screening and under treatment every 12 weeks until progression, and 4 weeks after last dose. Time to deterioration (TTD; decrease by 5 points) and mean change from baseline was measured for QLQ-C30 domains. Formal statistic testing was not performed. Results: The median follow-up for DUR-TREM vs. DOX were 34.0 mo. (25.6-42.2) and 37.9 mo. (31.5-37.9). The median duration of therapy was 2.8 (0-13) and 2.1 (0-4) mo., respectively. 86 of 92 (93.5%) patients had ≥1 PRO assessments and were included into the analyses. The completion rate at week 12 was 41.3%. Mean baseline global health status (GHS) was 54.1 (SD: 25.64) and 56.5 (SD: 28.47), respectively. GHS above the median was associated with improved OS and PFS in both arms, indicating a possible predictive biomarker. Under treatment, changes in PRO domains at 12 weeks were noted. TTD favored DUR-TRE in selected functional and symptom domains. Details will be shown at the meeting. Conclusions: MEDISARC is the first study to compare check-point inhibitor and doxorubicin treatment in sarcoma patients. PRO measures from baseline to week 12 favored DUR-TRE. Overall, results indicated better symptom and quality of life in patients treated with DUR-TRE. Clinical trial information: NCT03317457. [Table: see text]